Who are Biodexa Pharmaceuticals Plc's main suppliers?

Biodexa Pharmaceuticals Plc (BDRX) key suppliers include: CG Oncology, Inc., CG Oncology, Inc., CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc., CRISPR Therapeutics AG and 9 more. View the full supplier network at chainsifter.com/chain/BDRX.

Who are Biodexa Pharmaceuticals Plc's major customers?

Biodexa Pharmaceuticals Plc (BDRX) key customers include: Cogent Biosciences, Inc., Cogent Biosciences, Inc., CRISPR Therapeutics AG, CRISPR Therapeutics AG, GSK plc and 22 more. View the full customer network at chainsifter.com/chain/BDRX.

What sector is Biodexa Pharmaceuticals Plc in?

Biodexa Pharmaceuticals Plc (BDRX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Biodexa Pharmaceuticals Plc Supplier List (BDRX): 14 Verified Suppliers

14Suppliers

27Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Biodexa Pharmaceuticals Plc (BDRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

50Total relationships

2Distinct source URLs

9High confidence

0.738Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Biodexa Pharmaceuticals Plc Suppliers

Ticker	Name	Confidence	Evidence
CGON	CG Oncology, Inc.	72%	Reciprocal relationship from CGON graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, t…
CGON	CG Oncology, Inc.	72%	l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state…
CNSP	CNS Pharmaceuticals, Inc.	72%	ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co…
CNSP	CNS Pharmaceuticals, Inc.	72%	Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceutic…
CRSP	CRISPR Therapeutics AG	72%	Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceutic…
CRSP	CRISPR Therapeutics AG	72%	ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co…
PSTV	Plus Therapeutics, Inc.	72%	ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co…
PSTV	Plus Therapeutics, Inc.	72%	Reciprocal relationship from PSTV graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing a…
RXRX	Recursion Pharmaceuticals, Inc.	72%	Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state author…
RXRX	Recursion Pharmaceuticals, Inc.	72%	l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state…
SABSW	SABSW	72%	ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately 30 private co…
SABSW	SABSW	72%	Reciprocal relationship from SABSW graph: Reciprocal relationship from BDRX graph: ll therapies by Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing …
TARA	Protara Therapeutics, Inc.	72%	l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the state…
TARA	Protara Therapeutics, Inc.	72%	Reciprocal relationship from TARA graph: Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, t…

Biodexa Pharmaceuticals Plc Customers

Ticker	Name	Confidence	Evidence
COGT	Cogent Biosciences, Inc.	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
COGT	Cogent Biosciences, Inc.	72%	Reciprocal relationship from COGT graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v…
CRSP	CRISPR Therapeutics AG	72%	Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, con…
CRSP	CRISPR Therapeutics AG	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from GSK grap…
GSK	GSK plc	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
MANU	Manchester	72%	Reciprocal relationship from MANU graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from MANU graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from MANU g…
MANU	Manchester	72%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…
RXRX	Recursion Pharmaceuticals, Inc.	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
RXRX	Recursion Pharmaceuticals, Inc.	72%	Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v…
SABS	SAB Biotherapeutics, Inc.	72%	Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v…
SABS	SAB Biotherapeutics, Inc.	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
SLN	Silence Therapeutics plc	72%	Reciprocal relationship from SLN graph: Reciprocal relationship from BDRX graph: ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting per…
SLN	Silence Therapeutics plc	72%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…
TPST	Tempest Therapeutics, Inc.	72%	Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, v…
TPST	Tempest Therapeutics, Inc.	72%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
ASSUREX-HEALTH-INC	ASSUREX-HEALTH-INC	62%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	ons in the ELOC, by us to the Investor at our discretion from time to time until a Termination Event (as defined in the ELOC). The purchase price for Depositary Shares that we may sell to the Investo…
KV-PHARMACEUTICALS-CO	KV-PHARMACEUTICALS-CO	62%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…
MADRID-SPAIN-MIDATECH-LTD	MADRID-SPAIN-MIDATECH-LTD	62%	ons in the ELOC, by us to the Investor at our discretion from time to time until a Termination Event (as defined in the ELOC). The purchase price for Depositary Shares that we may sell to the Investo…
MIDATECH-LTD-MIDATECH-PHARMA-PLC	MIDATECH-LTD-MIDATECH-PHARMA-PLC	62%	ons in the ELOC, by us to the Investor at our discretion from time to time until a Termination Event (as defined in the ELOC). The purchase price for Depositary Shares that we may sell to the Investo…
REGUS-PLC	REGUS-PLC	62%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…
TEMPEST-THERAPEUTICS-INC-PANBELA-THERAPEUTICS-IN	TEMPEST-THERAPEUTICS-INC-PANBELA-THERAPEUTICS-IN	62%	ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · require additional post-market clinical tri…
UNITED-KINGDOM-COMPANY	UNITED-KINGDOM-COMPANY	62%	ons in the ELOC, by us to the Investor at our discretion from time to time until a Termination Event (as defined in the ELOC). The purchase price for Depositary Shares that we may sell to the Investo…
U-S-LISTED-COMPANY	U-S-LISTED-COMPANY	62%	ons in the ELOC, by us to the Investor at our discretion from time to time until a Termination Event (as defined in the ELOC). The purchase price for Depositary Shares that we may sell to the Investo…
WORKING-GROUP	WORKING-GROUP	62%	ement between the European Union and the United Kingdom contains an Annex in relation to medicinal products with the objective of facilitating availability of medicines, promotion of public health an…
XANODYNE-PHARMACEUTICALS-INC	XANODYNE-PHARMACEUTICALS-INC	62%	ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized over the vesting period using the straigh…

Biodexa Pharmaceuticals Plc Debt Obligations

Instrument	Description	Confidence	Evidence
BDRX-DEBT	Debt stack $82,054	90%	Market cache reports total debt of $82,054.

Biodexa Pharmaceuticals Plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Biodexa Pharmaceuticals Plc.

Biodexa Pharmaceuticals Plc Ownership

Holder	Name	Confidence	Evidence
BDRX-OWNER-HRT-FINANCIAL-LP	HRT Financial LP	95%	13F/ownership overlay lists HRT Financial LP; shares held 2,117; ownership 0.28%; value $9,357; as of 2025-12-31.
BDRX-OWNER-UBS-GROUP-AG	UBS Group AG	95%	13F/ownership overlay lists UBS Group AG; shares held 25; value $110; as of 2026-03-31.
BDRX-OWNER-ARMISTICE-CAPITAL-LLC	Armistice Capital, LLC	95%	13F/ownership overlay lists Armistice Capital, LLC; shares held 20,000; ownership 2.68%; value $88,400; as of 2025-12-31.
BDRX-OWNER-SBI-SECURITIES-CO-LTD	SBI Securities Co., Ltd.	95%	13F/ownership overlay lists SBI Securities Co., Ltd.; shares held 151; ownership 0.02%; value $667; as of 2026-03-31.
BDRX-OWNER-HILTON-HEAD-CAPITAL-PARTNERS-LLC	Hilton Head Capital Partners, LLC	95%	13F/ownership overlay lists Hilton Head Capital Partners, LLC; shares held 6; value $26; as of 2026-03-31.
BDRX-OWNER-RHUMBLINE-ADVISERS	Rhumbline Advisers	95%	13F/ownership overlay lists Rhumbline Advisers; shares held 5; value $22; as of 2025-12-31.
BDRX-OWNER-SABBY-MANAGEMENT-LLC	Sabby Management, LLC	95%	13F/ownership overlay lists Sabby Management, LLC; shares held 38,132; ownership 5.11%; value $168,543; as of 2025-12-31.
BDRX-OWNER-GAMMA-INVESTING-LLC	Gamma Investing LLC	95%	13F/ownership overlay lists Gamma Investing LLC; shares held 2,756; ownership 0.37%; value $12,181; as of 2026-03-31.

Biodexa Pharmaceuticals Plc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BCAX	Bicara Therapeutics Inc.	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
EBS	Emergent BioSolutions Inc.	100.00	2
BANL	CBL International Limited	100.00	2
SABSW	SAB Biotherapeutics, Inc.	100.00	1	['supplier']
AAUAF	Almaden Minerals Ltd.	100.00	2
CGON	CG Oncology, Inc.	100.00	1	['supplier']
BNRG	Brenmiller Energy Ltd	100.00	2
AZN	AstraZeneca PLC	100.00	2
RYAOF	Ryanair Holdings plc	100.00	2
ALGM	Allegro MicroSystems, Inc.	100.00	2
AUGO	Aura Minerals Inc.	100.00	2
DEO	Diageo plc	100.00	2
CBAN	Colony Bankcorp, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
ALCY	Alchemy Investments Acquisition Corp 1	100.00	2
CNSP	CNS Pharmaceuticals, Inc.	100.00	1	['supplier']
SDGR	Schrödinger, Inc.	100.00	2
TARA	Protara Therapeutics, Inc.	100.00	1	['supplier']

Biodexa Pharmaceuticals Plc Supply Chain